HbA1c ReductionWeChat-delivered medical nutrition therapy (WeMNT)

Clinical evidence dossier

WeChat-delivered medical nutrition therapy (WeMNT)

HbA1c

Evidence signal

Evidence signal

Strong

This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.

Evidence snapshot

Authoritative support records
3
Supporting studies available for review
3
Randomized trials
3
Reported effects
5

Clinical conclusion

WeChat-delivered medical nutrition therapy (WeMNT) shows a strong positive evidence signal for improving HbA1c across the studied comparisons.

Observed effects

Observed study estimates; not a pooled treatment effect.

Change from baseline

Absolute change

−0.689 percentage to −0.689 percentage

1 eligible estimates8–8 weeksObserved median: −0.689 percentage

Between-group effect

Mean difference

−0.49 percentage to −0.49 percentage

1 eligible estimates12–12 weeksObserved median: −0.49 percentage

Evidence composition

Non-randomized studies
0
Other designs
0
Unresolved designs
0
Magnitude-eligible effects
2

Consistency

Consistency classification

Consistent

Positive
3
No effect
0
Mixed
0
Negative
0

Population and applicability

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.

View reported population descriptions

These descriptions are reported across the supporting studies; they are not a single synthesized population.

  • Adults diagnosed with Type 2 diabetes.
  • Individuals seeking weight loss through medical or surgical interventions.
  • Patients seeking digital health interventions.
  • Pregnant women diagnosed with gestational diabetes.
  • Women seeking dietary management options during pregnancy.

Limitations

  • Evidence uses heterogeneous comparison contexts: baseline_within_group, usual_care.
  • 2 of 3 studies with duration data have follow-up of 12 weeks or less.

Supporting evidence

Inspect the authoritative studies and omitted support records for this dossier.

View supporting evidence